Benefits of resection for metachronous lung cancer Richard J Battafarano, MD, PhD, Seth D Force, MD, Bryan F Meyers, MD, Jennifer Bell, BSN, Tracey J Guthrie, BSN, Joel D Cooper, MD, G.Alexander Patterson, MD The Journal of Thoracic and Cardiovascular Surgery Volume 127, Issue 3, Pages 836-842 (March 2004) DOI: 10.1016/j.jtcvs.2003.08.055
Figure 1 Five-year actuarial survival from the time of the first resection of the entire group stratified by the stage of the primary NSCLC. The Journal of Thoracic and Cardiovascular Surgery 2004 127, 836-842DOI: (10.1016/j.jtcvs.2003.08.055)
Figure 2 Five-year actuarial survival from the time of the second resection of the entire group stratified by the stage of the metachronous NSCLC. The Journal of Thoracic and Cardiovascular Surgery 2004 127, 836-842DOI: (10.1016/j.jtcvs.2003.08.055)
Figure 3 Five-year actuarial survival from the time of the second resection of the entire group stratified by tumor histology. The Journal of Thoracic and Cardiovascular Surgery 2004 127, 836-842DOI: (10.1016/j.jtcvs.2003.08.055)
Figure 4 Five-year actuarial survival from the time of the second resection of the entire group stratified by the interval between resections. The Journal of Thoracic and Cardiovascular Surgery 2004 127, 836-842DOI: (10.1016/j.jtcvs.2003.08.055)